ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Studies related to compound BCR-ABL mutations can help in early determination of drug resistance, to find out complex mechanisms of multi-drug resistance and help in designing new drugs for multiple / compound mutant CML cases (Hochhaus et al., 2020; Soverini et al., 2020).